TY - JOUR
T1 - Enhancing contrast of magnetic resonance imaging in patients with liver cirrhosis
T2 - Conveyance times of primovist in hepatobiliary system
AU - Elbakkoush, Abdallah Ahmed
AU - Khaleel, Anas
AU - Atique, Suleman
AU - Mohamed, Albakush Nura Ahmed
AU - Sowe, Isatou
AU - Liu, Chien Tsai
N1 - Funding Information:
This study was supported by National Yang Ming University. Special thanks to Lin Joe and Prof Ran Chen Chiu for helping in data collection. The authors would also like to thank Renai Hospital for guidance in the study.
PY - 2017/4
Y1 - 2017/4
N2 - Purpose: To determine transit times for excretion of gadoxetic acid (Gd-EOB-DTPA), a recent magnetic resonance imaging (MRI) contrast agent, in hepatobiliary system of patients with liver cirrhosis. Methods: Liver cirrhosis patients that underwent contrast MRI examination at Renai Hospital, Taipei City, Taiwan were included. The patients who have experienced contrast-enhanced abdominal MR examination after injection of 10 mL Gd-EOB-DTPA at 1.5-T MR from December 2009 to March 2011, were included retrospectively. The images were evaluated for the presence of contrast agent in intra-hepatic bile ducts (IHD), common bile duct (CBD), gall bladder and duodenum. Results: The optimal time for arterial phase was from 15 s after injection while the optimal time for portal venous imaging was from 40 s after injection. Furthermore, the optimal time to observe changes was 20 min after contrast initiation of Gd-EOB-DTPA in 39 patients (83 %) in IHD and 37 patients (78.5 %) in CBD. Gall bladder reflux was visible in 26 patients (43 %), and duodenal excretion in 17 patients (36 %). After 30 min of contrast injection, Gd-EOB-DTPA could still be detected in 6 patients (13 %) in IHD and 7 patients (15 %) in CBD, while gall bladder reflux was visible in 10 patients (21 %), and duodenal excretion in 20 patients (55 %). Conclusion: The excretion of Gd-EOB-DTPA can be observed in liver cirrhosis patients.
AB - Purpose: To determine transit times for excretion of gadoxetic acid (Gd-EOB-DTPA), a recent magnetic resonance imaging (MRI) contrast agent, in hepatobiliary system of patients with liver cirrhosis. Methods: Liver cirrhosis patients that underwent contrast MRI examination at Renai Hospital, Taipei City, Taiwan were included. The patients who have experienced contrast-enhanced abdominal MR examination after injection of 10 mL Gd-EOB-DTPA at 1.5-T MR from December 2009 to March 2011, were included retrospectively. The images were evaluated for the presence of contrast agent in intra-hepatic bile ducts (IHD), common bile duct (CBD), gall bladder and duodenum. Results: The optimal time for arterial phase was from 15 s after injection while the optimal time for portal venous imaging was from 40 s after injection. Furthermore, the optimal time to observe changes was 20 min after contrast initiation of Gd-EOB-DTPA in 39 patients (83 %) in IHD and 37 patients (78.5 %) in CBD. Gall bladder reflux was visible in 26 patients (43 %), and duodenal excretion in 17 patients (36 %). After 30 min of contrast injection, Gd-EOB-DTPA could still be detected in 6 patients (13 %) in IHD and 7 patients (15 %) in CBD, while gall bladder reflux was visible in 10 patients (21 %), and duodenal excretion in 20 patients (55 %). Conclusion: The excretion of Gd-EOB-DTPA can be observed in liver cirrhosis patients.
KW - Common hepatic duct
KW - Gadoxetic acid
KW - Hepatocellular carcinoma
KW - Magnetic resonance imaging (MRI)
UR - http://www.scopus.com/inward/record.url?scp=85018413664&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018413664&partnerID=8YFLogxK
U2 - 10.4314/tjpr.v16i4.25
DO - 10.4314/tjpr.v16i4.25
M3 - Article
AN - SCOPUS:85018413664
SN - 1596-5996
VL - 16
SP - 919
EP - 924
JO - Tropical Journal of Pharmaceutical Research
JF - Tropical Journal of Pharmaceutical Research
IS - 4
ER -